Description

Soritmik (Sotalol Hydrochloride) Tablets 0.08 g. №20

Dosage: The usual adult dose is 80-160 mg twice daily. Dosage should be individualized based on the patient’s condition and response.

Indications: Soritmik tablets are indicated for the treatment of documented ventricular arrhythmias and certain supraventricular arrhythmias.

Contraindications: Soritmik tablets are contraindicated in patients with bronchial asthma, sinus bradycardia, heart block greater than first degree, and other conditions.

Directions: Take Soritmik tablets exactly as prescribed by your healthcare provider. Do not exceed the recommended dose without medical supervision.

Sotalol hydrochloride, the active ingredient in Soritmik tablets, is a non-selective beta-adrenergic receptor blocker with Class III antiarrhythmic properties. It prolongs the action potential duration and refractory period in cardiac tissues, exerting an antiarrhythmic effect. Studies have shown sotalol’s effectiveness in managing various types of arrhythmias, including atrial fibrillation and ventricular tachycardia.

Soritmik tablets should be used with caution in patients with renal impairment as dosage adjustments may be necessary. Regular monitoring of electrolytes and renal function is important during sotalol treatment. Inform your healthcare provider about all medications you are taking due to potential interactions.
Research studies have demonstrated sotalol’s efficacy in reducing atrial fibrillation recurrence and improving heart rate control. Clinical trials have shown sotalol’s safety and effectiveness in managing arrhythmias, making it a valuable option in treating cardiac rhythm disorders.
Compared to other antiarrhythmic agents, sotalol has shown comparable efficacy in controlling arrhythmias with a favorable safety profile. Its unique pharmacological properties make it a preferred choice for certain patients with specific arrhythmic conditions.